What we do Kwality Pharmaceuticals Ltd manufactures and exports diverse pharmaceutical formulations, specializing in complex injectables, beta lactams, oncology, and biologics, serving over 70 countries. |
Founded in 1,983 |
Market share Renowned for quality and regulatory approvals (EU GMP, WHO GMP), it commands a strong export presence across 80+ countries with growing market recognition. |
Problem solved Provides high-quality, affordable complex medicines including niche injectables and biologics to address global shortages and enhance healthcare access worldwide. |
Top clients or who we serve Serves pharmaceutical companies globally via out-licensing and supply agreements; caters to regulated, semi-regulated and emerging markets (B2B model). |
Key management Experienced leadership includes Mr. Ramesh Arora (MD & Chairman) with 42 years in pharma, supported by directors with deep industry expertise. |
Our journey and innovations Founded in 1983; expanded manufacturing units with EU GMP approvals; pioneered biologics and complex formulations; diversified into oncology, biosimilars, and niche therapies. |
Where we operate Exports to over 70 countries spanning Europe, Africa, Latin America, Asia, Middle East; strong presence in regulated and semi-regulated markets. |
Top products or what we offer Offers 1000+ products including liquid orals, tablets, capsules, injectables, oncology drugs, biosimilars, beta lactams, cephalosporins, and hormones. |
Top brands Not brand-centric; growth driven by product portfolio exceeding 1000 formulations across multiple therapeutic areas with EU GMP certification. |
Raw materials needed Active Pharmaceutical Ingredients (APIs), excipients, biologic substrates, chemical reagents, sterile packaging materials. |
Raw materials supplier Sources from domestic and international suppliers compliant with GMP standards; specific suppliers undisclosed. |
Recurring vs cyclical contribution Majority revenue recurring from out-licensing and supply contracts; steady export demand reduces cyclicality risks. |
Our industry position Emerging leader in complex and niche pharmaceuticals with certifications allowing access to regulated global markets; strong export-oriented growth. |
Financial highlights FY25 revenue INR 370 crore (~$48 million), PAT INR 40 crore (~$5.2 million), CAGR ~22%, expanding EBITDA and profit margins steadily. |
Geographical revenue split Revenue split nearly equal between Export INR 195 crore and Domestic INR 175 crore for FY25, supporting balanced growth. |
Order book - |
Whats driving growth Growth driven by capacity expansion, EU GMP certifications, complex product launches, biosimilars R&D, and increasing regulated market penetration. |
Our future plans Scaling biologics and oncology capacity, launching first biologic Erythropoietin, expanding R&D and manufacturing footprint with new plant by FY26. |
Our green promise Certified ISO 14001:2015; follows environmental norms with energy conservation, waste management, and sustainable manufacturing practices. |
Our people and values Over 1700 employees with strong focus on R&D (80+ scientists), quality, ethics, diversity and fostering continuous learning culture. |
Key challenges ahead Navigating regulatory compliances, resolving ongoing GST litigations, managing supply chain complexities, and competition in global pharma markets. |
Interesting facts Supplied high-demand injectables like Remdesivir globally during shortages; operates 4 out of 5 EU GMP approved plants; strong R&D with 600+ regulatory filings. |
Risks and strategy Mitigates risks through strict SOPs, diversified markets, continuous regulatory audits, and legal action on tax disputes to maintain compliance and growth. |
